Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.74 |
| ▸ | PPARG | P37231 | 4/20 | 0.67 |
| ▸ | CTSS | P25774 | 4/20 | 0.60 |
| ▸ | ACE | P12821 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 4/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | KLK7 | P49862 | 2/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL955526 | 1.00 | PPARA (0.74) | PPARAPPARGCTSSACECTSK | |
| SCHEMBL955527 | 1.00 | PPARA (0.74) | PPARAPPARGCTSSACECTSK | |
| SCHEMBL7442052 | 0.93 | PPARA (0.71) | PPARAPPARGCTSSACECTSK | |
| SCHEMBL7405992 | 0.93 | PPARA (0.71) | PPARAPPARGCTSSACECTSK | |
| SCHEMBL27897229 | 0.93 | PPARA (0.71) | PPARAPPARGCTSSACECTSK | |
| SCHEMBL8615711 | 0.91 | PPARA (0.69) | PPARAPPARGCTSSACECTSK | |
| SCHEMBL3348658 | 0.90 | PPARA (0.64) | PPARAPPARGCTSSACECTSK | |
| SCHEMBL3348663 | 0.90 | PPARA (0.64) | PPARAPPARGCTSSACECTSK | |
| SCHEMBL11901546 | 0.90 | PPARA (0.64) | PPARAPPARGCTSSACECTSK | |
| SCHEMBL20899650 | 0.90 | PPARA (0.82) | PPARAPPARGCTSSACECTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125383-A1 | INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-02-12 | — | — | US | disclosed |
| US-12472165-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-11-18 | — | — | US | disclosed |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN THERAPEUTICS LTD (US) | 2025-10-30 | — | — | US | disclosed |
| US-12295942-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-05-13 | — | — | US | disclosed |
| US-12213965-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-02-04 | — | — | US | disclosed |
| US-12005047-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| US-12005046-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240091205-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2024-03-21 | — | — | US | disclosed |
| US-20180037557-A1 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| CN-107567438-A | Riluzole prodrug and application thereof | 拜尔哈文制药股份有限公司 | 2018-01-09 | — | — | CN | disclosed |
| US-9394297-B2 | Amides as pim inhibitors | AMGEN INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150329538-A1 | AMIDES AS PIM INHIBITORS | AMGEN INC. (US) | 2015-11-19 | — | — | US | disclosed |
| EP-2809655-B1 | BENZIIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS SODIUM CHANNEL MODULATORS | PFIZER (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8927587-B2 | Chemical compounds | PFIZER LIMITED (GB) | 2015-01-06 | — | — | US | disclosed |
| US-20130274243-A1 | Chemical Compounds | PFIZER LTD (GB) | 2013-10-17 | — | — | US | disclosed |
| WO-2013130660-A1 | AMIDES AS PIM INHIBITORS | AMGEN INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20110275673-A1 | INHIBITORS OF SPHINGOSINE KINASE 1 | GENZYME CORPORATION | 2011-11-10 | — | — | US | disclosed |
| WO-2010033701-A2 | INHIBITORS OF SPHINGOSINE KINASE 1 | GENZYME CORPORATION (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | IL6ST, GFRA3, GFRA1 | PPARA 4425/4885PPARG 4266/4885CTSS 1265/4885 |
| US-20130274243-A1 | Chemical Compounds | SCN8A, SCN5A, KCNJ8 | PPARA 4206/4885PPARG 2994/4885CTSS 3573/4885 |
| US-12005046-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | PPARA 4317/4885PPARG 4202/4885CTSS 653/4885 |
| US-20110275673-A1 | INHIBITORS OF SPHINGOSINE KINASE 1 | SPHK1, SPHK2, S1PR1 | PPARA 2761/4885PPARG 3106/4885CTSS 1490/4885 |
| US-12005047-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | PPARA 4317/4885PPARG 4202/4885CTSS 653/4885 |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | GFRA3, IL6ST, GFRA1 | PPARA 4461/4885PPARG 4310/4885CTSS 1454/4885 |
| US-12472165-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | PPARA 4317/4885PPARG 4202/4885CTSS 653/4885 |
| US-12295942-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | PPARA 4317/4885PPARG 4202/4885CTSS 653/4885 |
| US-20260125383-A1 | INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | CGAS, PRKG1, GMPS | PPARA 4559/4885PPARG 3720/4885CTSS 1861/4885 |
| US-20150329538-A1 | AMIDES AS PIM INHIBITORS | PIM1, PIM3, PIM2 | PPARA 1196/4885PPARG 1321/4885CTSS 3374/4885 |
| US-20180037557-A1 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | APEH, CYP2C9, ALDH1A2 | PPARA 4295/4885PPARG 4288/4885CTSS 440/4885 |
| US-20240091205-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | PPARA 4402/4885PPARG 4422/4885CTSS 503/4885 |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | PPARA 4317/4885PPARG 4202/4885CTSS 653/4885 |
| US-12213965-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | PPARA 4317/4885PPARG 4202/4885CTSS 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.